Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | GPR35 | Q9HC97 | 3/20 | 0.48 |
| ▸ | CES2 | O00748 | 1/20 | 0.47 |
| ▸ | CES1 | P23141 | 1/20 | 0.47 |
| ▸ | APEX1 | P27695 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CASP6 | P55212 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | DNA2 | P51530 | 1/20 | 0.41 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17819747 | 1.00 | TDP1 (0.64) | TDP1L3MBTL1TSHRGPR35CES2 | |
| SCHEMBL1554602 | 0.86 | TDP1 (0.75) | TDP1L3MBTL1TSHRGPR35APEX1 | |
| SCHEMBL4688384 | 0.84 | TDP1 (0.50) | TDP1L3MBTL1TSHRGPR35CES2 | |
| SCHEMBL25176225 | 0.84 | TDP1 (0.53) | TDP1L3MBTL1TSHRGPR35CES2 | |
| SCHEMBL16108925 | 0.84 | TDP1 (0.49) | TDP1L3MBTL1TSHRGPR35CES2 | |
| SCHEMBL16044470 | 0.84 | TDP1 (0.53) | TDP1L3MBTL1TSHRGPR35CES2 | |
| SCHEMBL793112 | 0.84 | TDP1 (0.49) | TDP1L3MBTL1TSHRGPR35CES2 | |
| SCHEMBL21749965 | 0.83 | TDP1 (0.51) | TDP1L3MBTL1TSHRCA1CA2 | |
| Hydrogen Sulfide SCHEMBL28004578 | 0.82 | TDP1 (0.70) | TDP1L3MBTL1TSHRGPR35APEX1 | |
| SCHEMBL21248524 | 0.81 | MAPK1 (0.54) | TDP1L3MBTL1MAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 318 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118184679-A | Photothermal agent and preparation method thereof, photothermal nanoparticle and preparation method thereof, insulating material and self-repairing method of insulating material | 中国石油天然气股份有限公司 | 2024-06-14 | — | — | CN | claimed |
| EP-3943494-A1 | QUINAZOLINONES AS INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | ICOS CORPORATION (US) | 2022-01-26 | — | — | EP | claimed |
| US-10906907-B2 | Tert-butyl (s)-(1-(5-fluoro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)propyl)carbamate precursor of a quinazolinone inhibitor of human phosphatidylinositol 3-kinase delta and a process for preparing thereof | ICOS CORPORATION (US) | 2021-02-02 | — | — | US | claimed |
| WO-2017191608-A1 | NOVEL PROCESS FOR PREPARATION OF IDELALISIB | LAURUS LABS LIMITED (IN) | 2017-11-09 | — | — | WO | claimed |
| WO-2016108206-A2 | PROCESSES FOR PREPARATION OF IDELALISIB AND INTERMEDIATES THEREOF | DR. REDDY’S LABORATORIES LIMITED (IN) | 2016-07-07 | — | — | WO | claimed |
| US-12630516-B2 | Compounds | NRG THERAPEUTICS LTD. (GB) | 2026-05-19 | — | — | US | disclosed |
| EP-4208442-B1 | MPTP INHIBITORS | NRG THERAPEUTICS LTD (GB) | 2025-10-22 | — | — | EP | disclosed |
| CN-120117999-A | Fluorotranilast derivatives and medical application thereof | 中国药科大学 | 2025-06-10 | — | — | CN | disclosed |
| US-20250179028-A1 | ACRYLAMIDE COMPOUNDS | NRG THERAPEUTICS LTD (GB) | 2025-06-05 | — | — | US | disclosed |
| US-12221448-B2 | Selective PI3Kδ inhibitor and use thereof | Tarapeutics Science Inc. (CN) | 2025-02-11 | — | — | US | disclosed |
| EP-4486721-A1 | ACRYLAMIDE COMPOUNDS | NRG Therapeutics LTD (GB) | 2025-01-08 | — | — | EP | disclosed |
| US-20240360085-A1 | Glucose Uptake Inhibitors | KADMON CORPORATION, LLC (US) | 2024-10-31 | — | — | US | disclosed |
| US-4346034-A | Process for preparing imidazodiazepines | HOFFMANN-LA ROCHE INC. (US) | 1982-08-24 | — | — | US | disclosed |
| US-4346032-A | ANTIDOTES TO OVERDOSES OF BENZODIAZEPINE TRANQUILIZERS | HOFFMANN-LA ROCHE INC. (US) | 1982-08-24 | — | — | US | disclosed |
| US-4346030-A | ANTIDOTES FOR OVERDOSES OF BENZODIAZEPINE TRANQUILIZERS | HOFFMANN-LA ROCHE INC. (US) | 1982-08-24 | — | — | US | disclosed |
| US-4346031-A | Process for preparing imidazodiazepines | HOFFMANN-LA ROCHE INC. (US) | 1982-08-24 | — | — | US | disclosed |
| US-4346035-A | Process for preparing imidazodiazepines | HOFFMANN-LA ROCHE INC. (US) | 1982-08-24 | — | — | US | disclosed |
| US-4346036-A | ALKYLATION; AMIDATION; TRANQUILIZER ANTAGONIST | HOFFMANN-LA ROCHE INC. (US) | 1982-08-24 | — | — | US | disclosed |
| US-4316839-A | Imidazodiazepine derivatives | HOFFMAN-LA ROCHE INC. (US) | 1982-02-23 | — | — | US | disclosed |
| EP-0027214-A1 | Imidazodiazepine derivatives, process and intermediates for their preparation, medicaments containing them and their therapeutic application | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1981-04-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12630516-B2 | Compounds | CYP4B1, CYP1B1, NR4A1 | TDP1 3531/4885L3MBTL1 3747/4885TSHR 1589/4885 |
| US-20250179028-A1 | ACRYLAMIDE COMPOUNDS | ACR, CCNI, FANCI | TDP1 607/4885L3MBTL1 3937/4885TSHR 4232/4885 |
| US-20240360085-A1 | Glucose Uptake Inhibitors | SLC2A3, SLC2A1, SLC2A4 | TDP1 3799/4885L3MBTL1 3239/4885TSHR 2854/4885 |
| US-12221448-B2 | Selective PI3Kδ inhibitor and use thereof | PIK3CA, PIK3CD, PIK3R2 | TDP1 1289/4885L3MBTL1 2308/4885TSHR 1925/4885 |
| US-10906907-B2 | Tert-butyl (s)-(1-(5-fluoro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)propyl)carbamate precursor of a quinazolinone inhibitor of human phosphatidylinositol 3-kinase delta and a process for preparing thereof | PIK3CD, PIK3CA, PIK3CB | TDP1 619/4885L3MBTL1 3859/4885TSHR 2357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.